Stock Research for ARDM

ARDM

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ARDM Stock Chart & Research Data

The ARDM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARDM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ARDM Due diligence Resources & Stock Charts

The ARDM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARDM Detailed Price Forecast - CNN Money CNN View ARDM Detailed Summary - Google Finance
Yahoo View ARDM Detailed Summary - Yahoo! Finance Zacks View ARDM Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ARDM Trends & Analysis - Trade-Ideas Barrons View ARDM Major Holders - Barrons
NASDAQ View ARDM Call Transcripts - NASDAQ Seeking View ARDM Breaking News & Analysis - Seeking Alpha
Spotlight View ARDM Annual Report - CompanySpotlight.com OTC Report View ARDM OTC Short Report - OTCShortReport.com
TradeKing View ARDM Fundamentals - TradeKing Charts View ARDM SEC Filings - Bar Chart
WSJ View Historical Prices for ARDM - The WSJ Morningstar View Performance/Total Return for ARDM - Morningstar
MarketWatch View the Analyst Estimates for ARDM - MarketWatch CNBC View the Earnings History for ARDM - CNBC
StockMarketWatch View the ARDM Earnings - StockMarketWatch MacroAxis View ARDM Buy or Sell Recommendations - MacroAxis
Bullish View the ARDM Bullish Patterns - American Bulls Short Pains View ARDM Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ARDM Stock Mentions - StockTwits PennyStocks View ARDM Stock Mentions - PennyStockTweets
Twitter View ARDM Stock Mentions - Twitter Invest Hub View ARDM Investment Forum News - Investor Hub
Yahoo View ARDM Stock Mentions - Yahoo! Message Board Seeking Alpha View ARDM Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ARDM - SECform4.com Insider Cow View Insider Transactions for ARDM - Insider Cow
CNBC View ARDM Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARDM - OTC Markets
Yahoo View Insider Transactions for ARDM - Yahoo! Finance NASDAQ View Institutional Holdings for ARDM - NASDAQ


Stock Charts

FinViz View ARDM Stock Insight & Charts - FinViz.com StockCharts View ARDM Investment Charts - StockCharts.com
BarChart View ARDM Stock Overview & Charts - BarChart Trading View View ARDM User Generated Charts - Trading View


Latest Financial News for ARDM

New Research Coverage Highlights Aradigm, Ultra Petroleum, TRI Pointe Group, Finisar, Tesla, and The Progressive — Consolidated Revenues, Company Growth, and Expectations for 2018
Posted on Monday April 16, 2018

NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...


Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Posted on Monday April 09, 2018

Stock Monitor: Bio-Path Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Aradigm Corp. (NASDAQ: ARDM ). If you ...


Aradigm Announces the EMA Has Completed Its Validation of the MAA Submission
Posted on Thursday April 05, 2018

Aradigm Corporation today announced the completed formal validation by the European Medicines Agency of the Marketing Authorisation Application for Linhaliq for the treatment of non-cystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas aeruginosa (P.


Aradigm reports 4Q loss
Posted on Friday March 23, 2018

On a per-share basis, the Hayward, California-based company said it had a loss of 28 cents. The specialty pharmaceutical company posted revenue of $2.4 million in the period. For the year, the company ...


Enter a stock symbol to view the stock details.